Compound ID | 165

Update compound information

Contezolid (MRX-4/MRX-1)

Class: Oxazolidinone

Spectrum of activity: Gram-positive
Details of activity: MRSA (methicillin resistant Staphylococcus aureus) and VRE (vancomycin resistant Enterococcus sp.) ABSSI infections.
Institute where first reported: MicuRx Pharmaceuticals, USA
Year first mentioned: 2014
Highest developmental phase: Phase 3 (NCT06081361)
Development status: Active (as of 2024)
Chemical structure(s):
Click here for structure editor
Molecular weight: 408.33
Iso. SMILES: C1CN(C=CC1=O)C2=C(C=C(C(=C2F)F)N3C[C@@H](OC3=O)CNC4=NOC=C4)F
InChI Key: SULYVXZZUMRQAX-NSHDSACASA-N
Can. SMILES: C1=CN(CCC1=O)C2=C(C=C(C(=C2F)F)N3C[C@H](CNC4=NOC=C4)OC3=O)F
InChI: InChI=1S/C18H15F3N4O4/c19-12-7-13(15(20)16(21)17(12)24-4-1-10(26)2-5-24)25-9-11(29-18(25)27)8-22-14-3-6-28-23-14/h1,3-4,6-7,11H,2,5,8-9H2,(H,22,23)/t11-/m0/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/25184541
Guide to Pharmacology: contezolid
Citations:
  • http://aac.asm.org/content/58/4/2418.full
  • https://www.newtbdrugs.org/pipeline/compound/contezolid-mrx-4mrx-1

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.